Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
about
Oncolytic viruses as therapeutic cancer vaccinesNew viruses for cancer therapy: meeting clinical needsCancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumorsIntelligent design: combination therapy with oncolytic virusesPreclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamideBiosafety considerations for attenuated measles virus vectors used in virotherapy and vaccinationCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesClinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptorCyclophosphamide enhances glioma virotherapy by inhibiting innate immune responsesDesign and application of oncolytic HSV vectors for glioblastoma therapy.Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer CellsAntitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virusPharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapyThe Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor MicroenvironmentFlt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor modelsToxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with ProdrugsVaccinia virus, a promising new therapeutic agent for pancreatic cancer.Oncolytic virotherapy as a personalized cancer vaccine.The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors.Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomasPharmacologic and chemical adjuvants in tumor virotherapy.The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progressEvolution of oncolytic viruses: novel strategies for cancer treatment.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Oncolytic virotherapy for multiple myeloma: past, present, and future.Advances in the design and development of oncolytic measles viruses.The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon.Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride.Evaluation of vesicular stomatitis virus mutant as an oncolytic agent against prostate cancer.Translational research in oncolytic measles virotherapy: early discoveries and future steps.
P2860
Q21245758-F4E63F0C-583D-4AC2-BDD4-FCB5B225A84AQ24567699-28633F1C-B56B-48C4-AD0C-9C942B513802Q24614856-98A75CC6-6377-4C14-BF2D-EC2C71CE783BQ24628227-8C5C9F64-E236-455A-9C0E-10F22E7AD590Q24647228-96B4B11E-AA3D-4C54-9B29-42B1B44D77B6Q26700080-6F5CC615-3B3A-46C8-8E10-5BA019B40952Q26863779-CA7F3FC5-605B-4AA8-9669-99A1E1E007ADQ27690634-ED92494A-DB27-4B70-BF1A-9F23B8030573Q34600345-7AC37567-B629-483C-AB23-66B3001C917DQ35036505-7B6D66CC-0E89-48DE-976A-F57C0D3C4096Q35559877-003FE145-A17F-4C94-8752-B737B5A7E06AQ35687743-3FB5545A-BDFB-4B6F-8CB5-15DE2BB25DCEQ35750059-1D1892A9-A2E4-4DD1-87AC-F40A3D28294BQ35864258-3AEE81B4-AD6A-49DA-875E-16AF676C79F5Q36221386-FB20ED2F-CB02-4C2B-A26C-0C9F6B66E8D7Q36266545-44914690-B81E-4FA4-AE98-0AD204FD932AQ36644898-7374D9C6-2851-4A87-A29B-C74D06A5531BQ36658280-AFCB9A6D-8355-481A-9B86-25E21B56F42FQ37010979-7E7C5EE7-CB5F-41D1-864B-AB57660953BFQ37073278-8A0EA27C-602C-4104-BCD4-F480547C9FA4Q37138701-07112E0B-A830-4038-9084-43BDF595A8B8Q37158473-6CF61EF4-F5A3-48E9-8A01-8834251D2BAEQ37171980-583B2E36-1FCA-4153-BFD2-A1277218F409Q37185367-EA6EB6D6-5C9B-42A8-A1BA-9BF7E36F7843Q37280354-6EBE0B41-59F4-4E61-9226-3FCC2D8943CAQ37386851-57318969-DA7A-40AC-A064-5AE28FB36984Q37492540-CFABB459-C2D0-45C1-AA49-FC53F303D4D8Q37561072-EBC0322E-FB78-4FC6-AFED-3308FCBCF1A2Q37899223-DF1EA638-DE34-4F7C-B9C1-E2F8C2792720Q37899230-C2D93893-493A-4CA8-A240-423E22BE6735Q38159802-A911325C-A15D-4749-B44E-031611ED99B0Q38223419-42BC267F-36AB-435A-A4F0-BD5CC57FAD9AQ38803056-E50A66FA-9E60-4773-B974-65FC349DDCCCQ38924566-A82C66B8-7D26-44EC-931C-3E1694659AEDQ39399591-A18D5432-114E-454C-ABD5-18B8AE73397AQ39618095-5B72F53E-9491-42CE-AE02-9714DE6FE1A0Q41379521-45375A59-7C70-40F3-B8C9-D8A2DB8BA835Q51725634-B6EF54AF-360A-4EEA-8D8A-43878CAF60F3
P2860
Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
@en
Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
@nl
type
label
Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
@en
Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
@nl
prefLabel
Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
@en
Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
@nl
P2093
P1433
P1476
Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
@en
P2093
E Antonio Chiocca
Hirokazu Kambara
Yoshinaga Saeki
P304
11255-11258
P356
10.1158/0008-5472.CAN-05-2278
P407
P577
2005-12-01T00:00:00Z